Viveve Medical, Inc. (VIVE) financial statements (2021 and earlier)

Company profile

Business Address 345 INVERNESS DRIVE SOUTH
ENGLEWOOD, CO 80112
State of Incorp. DE
Fiscal Year End December 31
SIC 3845 - Electromedical and Electrotherapeutic Apparatus (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments799913910
Cash and cash equivalents799913910
Receivables1111234
Inventory, net of allowances, customer advances and progress billings3554545
Inventory3554545
Other undisclosed current assets2222233
Total current assets:13161617221921
Noncurrent Assets
Property, plant and equipment3333333
Long-term investments and receivables1111112
Long-term investments1111112
Other noncurrent assets0000111
Total noncurrent assets:4444555
TOTAL ASSETS:17202121272425
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3345667
Accounts payable1112222
Accrued liabilities2232545
Debt111    
Total current liabilities:4355667
Noncurrent Liabilities
Long-term debt and lease obligation555443231
Long-term debt, excluding current maturities555443231
Liabilities, other than long-term debt0000011
Other liabilities0000011
Total noncurrent liabilities:555443332
Total liabilities:109109103939
Stockholders' equity
Stockholders' equity attributable to parent711111317(15)(14)
Common stock 0000 0
Additional paid in capital227226222217214168161
Accumulated deficit(220)(215)(211)(204)(198)(183)(175)
Total stockholders' equity:711111317(15)(14)
TOTAL LIABILITIES AND EQUITY:17202121272425

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Revenues2211111
Cost of revenue
(Cost of Goods and Services Sold)
(2)(1)(1)(1)(2)(1)(1)
Gross profit:00(0)0(0)(0)0
Operating expenses(5)(4)(5)(6)(7)(6)(8)
Operating loss:(4)(3)(5)(6)(7)(7)(8)
Nonoperating expense
(Other Nonoperating expense)
(0)(0)(0)(0)(0)(0)(0)
Interest and debt expense(0)(0)(0)(0)(8)(1)(1)
Other undisclosed loss from continuing operations before equity method investments, income taxes  (2)    
Loss from continuing operations before equity method investments, income taxes:(5)(4)(7)(6)(15)(8)(10)
Loss from equity method investments(0)(0)(0)(0)(0)(0)(0)
Net loss attributable to parent:(5)(4)(7)(6)(15)(8)(10)
Preferred stock dividends and other adjustments(1)(1)(1)(1)   
Other undisclosed net loss available to common stockholders, basic    (0)  
Net loss available to common stockholders, diluted:(6)(5)(8)(7)(15)(8)(10)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(5)(4)(7)(6)(15)(8)(10)
Comprehensive loss, net of tax, attributable to parent:(5)(4)(7)(6)(15)(8)(10)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: